Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 40 Carcinoma, Non-Small-Cell Lung 31 Triple Negative Breast Neoplasms 23 Nasopharyngeal Carcinoma 23 Stomach Neoplasms 22 Esophageal Neoplasms 20 Esophageal Squamous Cell Carcinoma 19 Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 14 Colorectal Neoplasms 12 Uterine Cervical Neoplasms 11 Sarcoma 10 Pancreatic Neoplasms 9 Lung Neoplasms 9 Recurrence 7 Neoplasm Metastasis 7 Melanoma 6 Liver Neoplasms 6 Hodgkin Disease 6 Cholangiocarcinoma 6 Biliary Tract Neoplasms 5 Advanced Gastric Cancer 5 Small Cell Lung Carcinoma 4 Osteosarcoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Advanced Solid Tumor 4 Solid Tumor 3 Respiratory Tract Diseases 3 Rectal Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1 camrelizumab 1 anlotinib 1 Radiotherapy 1 Induction Chemotherapy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ESCC × camrelizumab × Clear all

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Xijing Hospital

Phase NA Unknown

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡